Pacibekitug - Tourmaline Bio
Alternative Names: PF-04236921; PF-4236921; TOUR-006Latest Information Update: 26 Aug 2025
At a glance
- Originator Pfizer
- Developer Pfizer; Tourmaline Bio
- Class Anti-inflammatories; Antirheumatics; Cardiovascular therapies; Eye disorder therapies; Monoclonal antibodies
- Mechanism of Action Interleukin 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Cardiovascular disorders; Graves ophthalmopathy; Kidney disorders
- Preclinical Abdominal aortic aneurysm
- Discontinued Crohn's disease; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 13 Aug 2025 Preclinical trials in Abdominal aortic aneurysm in USA (unspecified route)
- 30 Jun 2025 Tourmaline completes a successful pre-IND interaction with the US FDA to conduct a phase II trial in abdominal aortic aneurysm
- 20 May 2025 Pharmacodynamics and adverse event data from a phase II TRANQUILITY trial for Kidney disorders released byTourmaline Bio